These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 29995236

  • 21. A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient.
    Jodai T, Yoshida C, Sato R, Kakiuchi Y, Sato N, Iyama S, Kimura T, Saruwatari K, Saeki S, Ichiyasu H, Fujii K, Tomita Y.
    Immun Inflamm Dis; 2019 Mar; 7(1):3-6. PubMed ID: 30461210
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab.
    Funazo TY, Nomizo T, Ozasa H, Tsuji T, Yasuda Y, Yoshida H, Sakamori Y, Nagai H, Hirai T, Kim YH.
    Sci Rep; 2019 Nov 19; 9(1):17085. PubMed ID: 31745135
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody.
    Shiba M, Inaba H, Ariyasu H, Kawai S, Inagaki Y, Matsuno S, Iwakura H, Yamamoto Y, Nishi M, Akamizu T.
    Intern Med; 2018 Jul 15; 57(14):2029-2034. PubMed ID: 29491310
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. A case report.
    Boswell L, Casals G, Blanco J, Jiménez A, Aya F, de Hollanda A, Halperin I, Arance AM, Mora M, Hanzu FA.
    J Diabetes Investig; 2021 Dec 15; 12(12):2263-2266. PubMed ID: 34048145
    [Abstract] [Full Text] [Related]

  • 29. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
    Yaura K, Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2021 Aug 15; 254(4):253-256. PubMed ID: 34373422
    [Abstract] [Full Text] [Related]

  • 30. A Case of Fulminant Type 1 Diabetes with Transient Production of Anti-Glutamic Acid Decarboxylase Antibody.
    Harada N, Nakayama H, Nomura M.
    Am J Case Rep; 2024 May 16; 25():e943590. PubMed ID: 38751092
    [Abstract] [Full Text] [Related]

  • 31. Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma.
    Munakata W, Ohashi K, Yamauchi N, Tobinai K.
    Int J Hematol; 2017 Mar 16; 105(3):383-386. PubMed ID: 27696192
    [Abstract] [Full Text] [Related]

  • 32. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
    Hoffner B, Leighl NB, Davies M.
    Cancer Treat Rev; 2020 Apr 16; 85():101979. PubMed ID: 32078962
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Nivolumab-Induced Fulminant Immune-Related Colitis Despite Infliximab in a Patient With NSCLC.
    Callens R, Tamsin A, van Zandweghe L.
    J Thorac Oncol; 2019 Mar 16; 14(3):e49-e50. PubMed ID: 30782382
    [No Abstract] [Full Text] [Related]

  • 35. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.
    Almutairi AR, Alkhatib N, Martin J, Babiker HM, Garland LL, McBride A, Abraham I.
    Crit Rev Oncol Hematol; 2019 Oct 16; 142():16-25. PubMed ID: 31326706
    [Abstract] [Full Text] [Related]

  • 36. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
    Okuma Y, Wakui H, Utsumi H, Sagawa Y, Hosomi Y, Kuwano K, Homma S.
    Clin Lung Cancer; 2018 Sep 16; 19(5):410-417.e1. PubMed ID: 29859759
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.